PFE

Cliff-and-replace story. Comirnaty + Paxlovid took total revenue from ~$100B (2022) to ~$63B (2025E); ~$17B of legacy revenue (Eliquis royalty split with $BMY ending 2028, Ibrance, Vyndaqel, Xeljanz, Xtandi) faces LOE 2026-2030. Seagen ($43B, 2023) is the structural bet: ADC platform (Padcev/$BLA-locked + Tukysa + Tivdak + Adcetris) inherited at peak Big Pharma ADC interest ($MRK/Daiichi, $JNJ, $AZN all bidding).

5B run-rate by end-2027. Balance sheet absorbed Seagen debt (~$60B net) - dividend at 7%+ yield is the disputed signal: management reaffirmed, market prices a cut.

BULL

- Seagen ADC franchise + oncology pipeline (>30 oncology programs) is the real replacement engine; Padcev approval expansions still un-modeled

- Cost takeout ($4.5B) lifts margins on flat top-line

- Dividend yield 7%+ with management commitment - if maintained, total return floor

- GLP-1 oral program restarted post-danuglipron with new candidates (PF-07976016)

- COVID franchise stabilizing at ~$8B floor (Comirnaty + Paxlovid combined), not zero

BEAR

- $17B LOE wall 2026-2030 vs pipeline that has not yet produced replacement scale

- Danuglipron oral GLP-1 failed (liver tox, 2026) - locks $LLY/$NVO out of reach in obesity

- Seagen synergies running below deal model; ADC space increasingly crowded ($MRK-Daiichi $22B, $JNJ-Ambrx)

- Dividend coverage on adjusted EPS thin; cut risk priced in (7%+ yield = market disbelief)

- FTC + IRA Medicare negotiation pressure on Eliquis, Ibrance, Xeljanz pricing